1. Norway Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Medistim ASA

Medistim ASA

284.00
NOK
+2.00
(+0.71%)
9.50EPS
24.48P/E
4.25BMarket Cap
Oct 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.52
11.84
13.8
14.47
16.3
17.77
19.62
19.57
22.94
26.65
28.53
30.72
38.29
41.31
Basic EPS, GAAP
1.47
1.73
2.23
2.15
2.62
3.14
3.87
3.81
4.99
6.25
5.68
5.67
8.71
9.5
Free Cash Flow per Basic Share
0.23
1.9
1.81
0.94
2.59
2.17
3.67
3.49
6.36
5.06
4.9
6.47
8.43
8.68
Dividend per Share
1.1
0.8
1.4
1.65
1.75
2
2.25
2.75
3
3.75
4.5
4.5
5.99
14.02
Book Value per Share
6.72
7.68
8.61
9.18
10.08
11.37
13.02
14.1
16.79
20.14
21.77
23.84
25.62
22.48
Tangible Book Value per Share
4.3
4.99
5.79
6.51
7.74
9.19
10.92
12.31
15.13
18.17
19.29
20.52
20.91
16.32
Basic Weighted Avg Shares
18
18
18
18
18
18
18
18
18
18
18
18
18
18
Sales/Revenue/Turnover
190
214
250
263
296
323
357
356
418
486
521
563
700
755
Operating Margin (%)
18.71
20.24
21.2
21.45
22.11
22.9
25.15
26.81
27.83
29.05
25.22
23.3
28.04
28.98
Depreciation Expense
8
8
13
12
13
12
18
23
23
23
24
15
16
9
Net Income, GAAP
27
31
40
39
48
57
70
69
91
114
104
104
159
174
Effective Tax Rate (%)
29.21
30.4
27.36
26.96
28.58
23.39
22.78
24.25
20.31
21.96
23.21
22.66
23.03
22.73
Profit Margin (%)
13.94
14.58
16.17
14.88
16.07
17.66
19.7
19.48
21.76
23.44
19.92
18.46
22.75
22.99
Working Capital
66
84
94
99
121
135
157
186
229
286
297
322
335
264
LT Debt
5
11
6
2
11
8
27
29
17
10
9
25
38
35
Total Equity
122
139
156
167
183
207
237
257
306
368
398
437
468
411
Return on Invested Capital (%)
18.64
19.16
20.43
21.98
22.87
24.81
25.99
23.57
27.39
28.41
23.17
21.04
28.03
36.04
Return on Capital (%)
21.89
22.13
25.15
23.18
25.88
27.66
28.89
24.49
29.18
31.96
26.05
23.5
33.18
37.06
Return on Common Equity (%)
22.41
23.97
27.38
24.22
27.21
29.28
31.7
28.11
32.3
33.83
27.12
24.88
35.18
39.56

Capital Structure

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
38
35
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
4,735
3,821
4,251

Working Capital

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
478
492
387
Cash, Cash Equivalents & STI
206
210
100
Accounts Receivable, Net
86
104
129
Inventories
161
160
156
Total Current Liabilities
143
130
123
Payables & Accruals
- -
- -
- -
ST Debt
12
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.71%
12.91%
7.28%
Free Cash Flow
29.83%
24.31%
30.12%
Net Income, GAAP
16.11%
20.16%
53.33%
Sales/Revenue/Turnover
11.04%
14.64%
24.38%
Total Cash Common Dividend
16.11%
17.52%
32.82%

Quarterly Revenue

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
134
145
133
151
563
2025
182
169
- -
182
700
2026
202
202
- -
- -
- -

Quarterly Earnings Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.33
1.9
1.28
1.16
5.67
2025
2.37
2.35
- -
2.08
8.71
2026
2.2
2.85
- -
- -
- -

Quarterly Dividends Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.5
2025
- -
6.02
- -
- -
5.99
2026
- -
8
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kari Eian Krogstad
Full Time Employees
159
Sector
Health technology
Industry
Medical specialties
Address
Oekernveien 94 Oslo PS Norway 0579
IPO Date
May 3, 2004
Website
medistim.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Medistim ASA develops, manufactures, services, leases and distributes medical devices that combine transit time flow measurement (TTFM) and high-frequency ultrasound imaging for cardiac, vascular and transplant surgery; its core products include the MiraQ Cardiac system for cardiac surgery, MiraQ Vascular for vascular and transplant procedures, MiraQ Ultimate for both cardiac and vascular applications, MiraQ INTUI software platform with intuitive controls, and associated imaging probes for intraoperative blood flow assessment and visualization of atherosclerosis. Founded in 1984 and headquartered in Oslo, Norway, the company serves surgeons and hospitals in the United States, Europe, Asia and other international markets, focusing on quality assurance to enhance surgical outcomes and reduce risks. In recent developments, Medistim strengthened its commercial operations in January 2025 by appointing a chief commercial officer and a new vice president of sales for the Americas; it launched the clinical PATENT study in November 2024 to evaluate TTFM and high-frequency ultrasound benefits in vascular surgery; the company introduced the MiraQ INTUI software platform following a successful early access program, with official rollout at the International Coronary Congress in December 2024; it also hosted a Capital Markets Day in December 2024 and reported record sales revenues, including 25.8% growth to MNOK 350.6 for the first half of 2025.